Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

The Clinical Utility of Immunoscore in Stage III CRC

June 14th 2019

Jerome Galon, PhD, research director, French Institute of Health and Medical Research, discusses the prognostic value of Immunoscore in stage III colorectal cancer.

Dr. Lieu on HER2-Directed Therapy in CRC

June 14th 2019

Christopher Lieu, MD, director, GI Medical Oncology Program and deputy associated director for clinical research, at the University of Colorado Cancer Center, discusses HER2-directed therapy for patients with colorectal cancer (CRC).

Dr. Davis on the Potential for Maintenance Therapy in Gastric Cancer

June 14th 2019

S. Lindsey Davis, MD, an assistant professor of medicine and gastrointestinal medical oncologist at the University of Colorado Cancer Center, discusses the potential for maintenance therapy in gastric cancer.

SM-88 Shows Efficacy in Pancreatic, Prostate Cancers

June 13th 2019

Having a late-stage treatment for pancreatic cancer that avoids many of the adverse events associated with chemotherapy would be a boon for patients.

Dr. Hall Discusses Rationale for the POLO Trial in Metastatic Pancreatic Cancer

June 13th 2019

Michael J. Hall, MD, MS, director, Gastrointestinal Risk Assessment, assistant professor, Fox Chase Cancer Center, discusses the rationale for the POLO trial in metastatic pancreatic cancer.

Dr. Bekaii-Saab on the Impact of the BEACON CRC Study in BRAF-Mutated CRC

June 13th 2019

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the impact of the BEACON CRC trial in patients with BRAF V600E-mutated metastatic colorectal cancer.

Future of mCRC Lies in Biomarker-Directed Therapies

June 12th 2019

Christopher Lieu, MD, highlights updates on biomarker-directed therapy with colorectal cancer and ongoing research being done with immunotherapy.

Ramucirumab/TAS-102 Combo Aims to Overcome Toxicities in Gastric/GEJ Cancer

June 12th 2019

Rutika Mehta, MD, MPH, provides insight on the ongoing study combining TAS-102 with ramucirumab in the treatment of patients with advanced gastric/GEJ cancer.

Dr. Lenz Discusses Frontline Nivolumab Plus Ipilimumab in mCRC

June 12th 2019

Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses frontline nivolumab plus ipilimumab in metastatic colorectal cancer.

Dr. El-Khoueiry on Choosing Between Lenvatinib and Sorafenib in HCC

June 12th 2019

Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, distinguishes between lenvatinib and sorafenib for the frontline treatment of advanced hepatocellular carcinoma.

Management of Newly Diagnosed mCRC Driven by Molecular Markers

June 11th 2019

Wells A. Messersmith, MD, discusses the evolving standards of care in colorectal cancer and the importance of molecular testing in guiding treatment decisions.

Dr. Nallapareddy on Treatment Options for Left- and Right-Sided CRC

June 11th 2019

Sujatha Nallapareddy, MD, gastrointestinal medical oncologist, Rocky Mountain Cancer Centers, discusses treatment options for left- and right-sided colorectal cancer.

Immunotherapy Generates Excitement in Gastric/GEJ Cancers

June 8th 2019

S. Lindsey Davis, MD, highlights the latest immunotherapy developments and other advances in gastric and gastroesophageal junction cancers.

Dr. Philip on the Impact of the PRODIGE 24/CCTG PA.6 Study in Pancreatic Cancer

June 7th 2019

Philip A. Philip, MD, PhD, FRCP, professor, Department of Oncology, Karmanos Cancer Institute, discusses the impact of the PRODIGE 24/CCTG PA.6 study in pancreatic cancer.

Dr. El-Rayes Discusses Methods of Locoregional Therapy in mCRC

June 7th 2019

Bassel El-Rayes, MD, chief clinical research scientist, Winship Cancer Institute of Emory University, discusses methods of locoregional therapy in metastatic colorectal cancer.

Dr. Sahai on the Role of Genomic Profiling in Pancreatic Cancer

June 7th 2019

Vaibhav Sahai, MBBS, assistant professor of medicine at the University of Michigan, discusses the role of genomic profiling in pancreatic cancer.

Dr. Kopetz on the Correlation Between Tumor Sidedness and Biomarkers in CRC

June 6th 2019

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the correlation between tumor sidedness and biomarkers in colorectal cancer.

Dr. Messersmith on Molecular Markers to be Aware of in CRC

June 5th 2019

Wells A. Messersmith, MD, co-director of the Developmental Therapeutics Program, and director, GI Cancer Program, at the University of Colorado School of Medicine, discusses molecular markers to be aware of in patients with colorectal cancer (CRC).

Laparoscopic Surgery Found to Be Noninferior to Open Surgery Method for CRC Liver Metastases

June 3rd 2019

Similar long-term rates of survival were seen in patients with colorectal cancer and liver metastases regardless of whether the patient underwent laparoscopic or open liver surgery.

Dr. Golan on the Phase III POLO Trial in BRCA-Mutant Pancreatic Cancer

June 3rd 2019

Talia Golan, MD, head of Sheba Pancreatic Cancer Center, discusses the results of the phase III POLO trial, which evaluated maintenance olaparib compared with placebo among patients with germline BRCA-mutated metastatic pancreatic cancer.